Comparing up-front intensive chemoimmunotherapy with ASCT consolidation vs bendamustine-rituximab
| . | Cytarabine-containing induction and ASCT consolidation followed by rituximab maintenance (3 y) . | Bendamustine-rituximab followed by rituximab maintenance (2 y) . |
|---|---|---|
| Median progression-free survival | 7-10 y *Nordic MCL2 study11 | 4.4-5.3 y *E1411 and SHINE studies49,50 |
| Median overall survival | ~10-13 y | ~10-13 y |
| Key toxicities | Alopecia, fatigue, severe myelosuppression, infection, graft failure (<1%), mucositis, GI toxicity, B-cell depletion, cardiopulmonary toxicity, liver toxicity, renal insufficiency, cognitive impairment, secondary malignancy | Fatigue, myelosuppression, infection, GI toxicity (mild), B-cell depletion, secondary malignancy |
| Quality-of-life considerations | *Hospitalization for transplant (or close proximity to hospital) *Seek care at a transplant center | *Maintain performance status without requirement for hospitalization *Can receive community-based care |
| . | Cytarabine-containing induction and ASCT consolidation followed by rituximab maintenance (3 y) . | Bendamustine-rituximab followed by rituximab maintenance (2 y) . |
|---|---|---|
| Median progression-free survival | 7-10 y *Nordic MCL2 study11 | 4.4-5.3 y *E1411 and SHINE studies49,50 |
| Median overall survival | ~10-13 y | ~10-13 y |
| Key toxicities | Alopecia, fatigue, severe myelosuppression, infection, graft failure (<1%), mucositis, GI toxicity, B-cell depletion, cardiopulmonary toxicity, liver toxicity, renal insufficiency, cognitive impairment, secondary malignancy | Fatigue, myelosuppression, infection, GI toxicity (mild), B-cell depletion, secondary malignancy |
| Quality-of-life considerations | *Hospitalization for transplant (or close proximity to hospital) *Seek care at a transplant center | *Maintain performance status without requirement for hospitalization *Can receive community-based care |